Drug intelligence / Profile preview

KJ13001

Development stage: Preclinical
Lead developer: Kukje Pharm
Modality: Small Molecules

Overview

KJ13001 is a small molecule therapeutic candidate currently in the discovery research stage, developed by Kukje Pharm. It is designed for the treatment of infectious diseases and is classified as an improved or modified new drug (IMD) in the South Korean regulatory context. The program specifically focuses on a high-dose formulation, which is typically intended to improve clinical efficacy, patient compliance, or the pharmacokinetic profile of the active anti-infective agent compared to standard dosing regimens.

Beyond the preview

Go deeper on KJ13001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KJ13001.

Explore the full profile